The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial
Abstract
PURPOSE: We report the clinical outcomes of a randomized trial comparing prophylactic whole-pelvic nodal radiotherapy to prostate-only radiotherapy (PORT) in high-risk prostate cancer. METHODS: This phase III, single center, randomized controlled trial enrolled eligible patients undergoing radical radiotherapy for node-negative prostate adenocarcinoma, with estimated nodal risk ≥ 20%. Randomization was 1:1 to PORT (68 Gy/25# to prostate) or whole-pelvic radiotherapy (WPRT, 68 Gy/25# to prostate, 50 Gy/25# to pelvic nodes, including common iliac) using computerized stratified block randomization, stratified by Gleason score, type of androgen deprivation, prostate-specific antigen at diagnosis, and prior transurethral resection of the prostate. All patients received image-guided, intensity-modulated radiotherapy and minimum 2 years of androgen deprivation therapy. The primary end point was 5-year biochemical failure-free survival (BFFS), and secondary end points were disease-free survival (DFS) and overall survival (OS). RESULTS: From November 2011 to August 2017, a total of 224 patients were randomly assigned (PORT = 114, WPRT = 110). At a median follow-up of 68 months, 36 biochemical failures (PORT = 25, WPRT = 7) and 24 deaths (PORT = 13, WPRT = 11) were recorded. Five-year BFFS was 95.0% (95% CI, 88.4 to 97.9) with WPRT versus 81.2% (95% CI, 71.6 to 87.8) with PORT, with an unadjusted hazard ratio (HR) of 0.23 (95% CI, 0.10 to 0.52; P < .0001). WPRT also showed higher 5-year DFS (89.5% v 77.2%; HR, 0.40; 95% CI, 0.22 to 0.73; P = .002), but 5-year OS did not appear to differ (92.5% v 90.8%; HR, 0.92; 95% CI, 0.41 to 2.05; P = .83). Distant metastasis-free survival was also higher with WPRT (95.9% v 89.2%; HR, 0.35; 95% CI, 0.15 to 0.82; P = .01). Benefit in BFFS and DFS was maintained across prognostic subgroups. CONCLUSION: Prophylactic pelvic irradiation for high-risk, locally advanced prostate cancer improved BFFS and DFS as compared with PORT, but OS did not appear to differ.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mottet, N., Bellmunt, J., Bolla, M., Briers, E., Cumberbatch, M. G., De Santis, M., Fossati, N., Gross, T., Henry, A. M., Joniau, S., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.08.003 · Cited by 3,227
Roach, M., Hanks, G., Thames, H., Schellhammer, P., Shipley, W. U., Sokol, G. H., & Sandler, H. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.04.029 · Cited by 2,749
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Mohler, J. L., Antonarakis, E. S., Armstrong, A. J., D’Amico, A. V., Davis, B. J., Dorff, T., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0023 · Cited by 1,532
Roach, M., DeSilvio, M., Lawton, C., Uhl, V., Machtay, M., Seider, M. J., Rotman, M., Jones, C., Asbell, S. O., Valicenti, R. K., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.004 · Cited by 637
Lawton, C. A., DeSilvio, M., Roach, M., Uhl, V., Kirsch, R., Seider, M., Rotman, M., Jones, C., Asbell, S., Valicenti, R., et al. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.04.003 · Cited by 480
Roach, M., Marquez, C., Yuo, H.-S., Narayan, P., Coleman, L., Nseyo, U. O., Navvab, Z., & Carroll, P. R. (1994) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(94)90138-4 · Cited by 461
Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer
Xie, W., Regan, M. M., Buyse, M., Halabi, S., Kantoff, P. W., Sartor, O., Soule, H., Clarke, N. W., Collette, L., Dignam, J. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.9987 · Cited by 433
Lawton, C. A., Michalski, J. M., Naqa, I. E., Buyyounouski, M. K., Lee, W. R., Ménard, C. M., O’Meara, E., Rosenthal, S. A., Ritter, M. A., & Seider, M. J. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.08.002 · Cited by 420
Zapatero, A., Guerrero, A., Maldonado, X., Alvarez, A., Segundo, C. G. S., Rodríguez, M. A. C., Macias, V., Olive, A. P., Casas, F., Boladeras, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70045-8 · Cited by 301
Roach, M., Moughan, J., Lawton, C. A. F., Dicker, A. P., Zeitzer, K. L., Gore, E. M., Kwok, Y., Seider, M. J., Hsu, I.-C., Hartford, A. C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30528-x · Cited by 234
Cited by
Pollack, A., Karrison, T. G., Balogh, A. G., Gomella, L. G., Low, D. A., Bruner, D. W., Wefel, J. S., Martin, A.-G., Michalski, J. M., Angyalfi, S. J., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01790-6 · Cited by 266
Gillessen, S., Armstrong, A., Attard, G., Beer, T. M., Beltran, H., Bjartell, A., Bossi, A., Briganti, A., Bristow, R. G., Bulbul, M., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.04.002 · Cited by 130
Self-citation
Metadata
- Authors
- Murthy, V., Maitre, P., Kannan, S., Panigrahi, G., Krishnatry, R., Bakshi, G., Prakash, G., Pal, M., Menon, S., Phurailatpam, R., Mokal, S., Chaurasiya, D., Popat, P., Sable, N., Agarwal, A., Rangarajan, V., Joshi, A., Noronha, V., Prabhash, K., & Mahantshetty, U.
- Venue
- Journal of Clinical Oncology
- Published
- 2021-04-10
- Volume
- 39
- Issue
- 11
- Pages
- 1234-1242
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W3125743225
- Cited by
- 345
- References
- 15
- FWCI
- 33.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial. https://app.cochat.ai/papers/10.1200/jco.20.03282
- The paper
- Murthy, V., Maitre, P., Kannan, S., Panigrahi, G., Krishnatry, R., Bakshi, G., Prakash, G., Pal, M., Menon, S., Phurailatpam, R., Mokal, S., Chaurasiya, D., Popat, P., Sable, N., Agarwal, A., Rangarajan, V., Joshi, A., Noronha, V., Prabhash, K., & Mahantshetty, U. (2021). Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.20.03282
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.